Palacio-Pastrana Claudia, Muñoz-Villegas Patricia, Dániel-Dorantes Fernando, Sánchez-Ríos Alejandra, Olvera-Montaño Oscar, Martínez-Montoya Yareni I, Quintana-Hau Juan D, Baiza-Durán Leopoldo M
SalaUno Salud, SAPI de CV, México City, México.
Regional Medical Affairs Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, México.
Med Devices (Auckl). 2022 Aug 24;15:293-305. doi: 10.2147/MDER.S379050. eCollection 2022.
To evaluate the rheological properties of the ophthalmic viscoelastic device (OVD) PRO-149, its preclinical safety, and its effectiveness when used during cataract surgery in patients with age-related cataract.
Control (HEC) and test (PRO-149) OVDs were compared through rheological measures, by two preclinical safety studies in rabbits, and under normal-use conditions during cataract removal and lens implantation in a parallel randomized clinical trial.
Rheological properties were determined. Preclinical studies did not find any evidence of safety issues or toxicity. In the clinical trial, 36 subjects were included. After 29 days, there were no statistically significant differences in mean percentage of endothelial cell count change or in the postoperative intraocular pressure between groups. There were no significant differences between OVDs for any safety parameter studied. Finally, PRO-149 showed a statistically significant improvement in surgeon rating for ease of use during extraction (p < 0.05).
PRO-149 is a dispersive OVD. The rabbit models did not find evidence of clinical alterations or toxicity. The results of the clinical study support that the two studied OVDs were clinically similar in terms of safety and effectiveness for cataract surgery.
The trial is registered at Clinical Trials.gov at NCT04702802 (21-01-11).
评估眼科粘弹性装置(OVD)PRO - 149的流变学特性、临床前安全性以及在年龄相关性白内障患者白内障手术中使用时的有效性。
通过流变学测量、在兔子身上进行的两项临床前安全性研究以及在一项平行随机临床试验中白内障摘除和晶状体植入的正常使用条件下,对对照(HEC)和测试(PRO - 149)OVD进行比较。
确定了流变学特性。临床前研究未发现任何安全问题或毒性证据。在临床试验中,纳入了36名受试者。29天后,两组之间内皮细胞计数变化的平均百分比或术后眼压在统计学上无显著差异。对于所研究的任何安全参数,OVD之间均无显著差异。最后,PRO - 149在外科医生对摘除过程中易用性的评分方面显示出统计学上的显著改善(p < 0.05)。
PRO - 149是一种分散型OVD。兔子模型未发现临床改变或毒性的证据。临床研究结果支持,在白内障手术的安全性和有效性方面,所研究的两种OVD在临床上相似。
该试验在ClinicalTrials.gov上注册,注册号为NCT04702802(21 - 01 - 11)。